Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer

Cell

Volumn 131, Issue 6, 2007, Pages 1190-1203

  Rikova, Klarisa ^a   Guo, Ailan ^a   Zeng, Qingfu ^a   Possemato, Anthony ^a   Yu, Jian ^a   Haack, Herbert ^a   Nardone, Julie ^a   Lee, Kimberly ^a   Reeves, Cynthia ^a   Li, Yu ^a   Hu, Yerong ^c   Tan, Zhiping ^c   Stokes, Matthew ^a   Sullivan, Laura ^a   Mitchell, Jeffrey ^a   Wetzel, Randy ^a   MacNeill, Joan ^a   Ren, Jian Min ^a   Yuan, Jin ^a   Bakalarski, Corey E ^b   Villen, Judit ^b   Kornhauser, Jon M ^a   Smith, Bradley ^a   Li, Daiqiang ^c   Zhou, Xinmin ^c   Gygi, Steven P ^b   Gu, Ting Lei ^a   Polakiewicz, Roberto D ^a   Rush, John ^a   Comb, Michael J ^a   more..

^a CELL SIGNALING TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

HUMDISEASE; PROTEINS; SIGNALING

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; HYBRID PROTEIN; IMATINIB; PHOSPHOTRANSFERASE; PHOSPHOTYROSINE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN ROS; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; ONCOGENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS;

EID: 36849065315     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2007.11.025     Document Type: Article

References (54)

1. Amann J., Kalyankrishna S., Massion P.P., Ohm J.E., Girard L., Shigematsu H., Peyton M., Juroske D., Huang Y., Stuart Salmon J., et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 65 (2005) 226-235
2. Blume-Jensen P., and Hunter T. Oncogenic kinase signalling. Nature 411 (2001) 355-365
3. Charest A., Wilker E.W., McLaughlin M.E., Lane K., Gowda R., Coven S., McMahon K., Kovach S., Feng Y., Yaffe M.B., et al. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res. 66 (2006) 7473-7481
4. Chin K., DeVries S., Fridlyand J., Spellman P.T., Roydasgupta R., Kuo W.L., Lapuk A., Neve R.M., Qian Z., Ryder T., et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10 (2006) 529-541
5. Dowell J.E., and Minna J.D. Chasing mutations in the epidermal growth factor in lung cancer. N. Engl. J. Med. 352 (2005) 830-832
6. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., and Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344 (2001) 1038-1042
7. Engelman J.A., Janne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., Cichowski K., Johnson B.E., and Cantley L.C. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA 102 (2005) 3788-3793
8. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007) 1039-1043
9. Everley P.A., Bakalarski C.E., Elias J.E., Waghorne C.G., Beausoleil S.A., Gerber S.A., Faherty B.K., Zetter B.R., and Gygi S.P. Enhanced analysis of metastatic prostate cancer using stable isotopes and high mass accuracy instrumentation. J. Proteome Res. 5 (2006) 1224-1231
10. Ford C.E., Lau S.K., Zhu C.Q., Andersson T., Tsao M.S., and Vogel W.F. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br. J. Cancer 96 (2007) 808-814
11. Gilchrist A., Au C.E., Hiding J., Bell A.W., Fernandez-Rodriguez J., Lesimple S., Nagaya H., Roy L., Gosline S.J., Hallett M., et al. Quantitative proteomics analysis of the secretory pathway. Cell 127 (2006) 1265-1281
12. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., et al. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007) 153-158
13. Gu T.L., Goss V.L., Reeves C., Popova L., Nardone J., Macneill J., Walters D.K., Wang Y., Rush J., Comb M.J., et al. Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood 108 (2006) 4202-4204
14. Hernandez L., Bea S., Bellosillo B., Pinyol M., Falini B., Carbone A., Ott G., Rosenwald A., Fernandez A., Pulford K., et al. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am. J. Pathol. 160 (2002) 1487-1494
15. Hernandez L., Pinyol M., Hernandez S., Bea S., Pulford K., Rosenwald A., Lamant L., Falini B., Ott G., Mason D.Y., et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 94 (1999) 3265-3268
16. Hornbeck P.V., Chabra I., Kornhauser J.M., Skrzypek E., and Zhang B. PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation. Proteomics 4 (2004) 1551-1561
17. Hu H., Bliss J.M., Wang Y., and Colicelli J. RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration. Curr. Biol. 15 (2005) 815-823
18. Kinch M.S., Moore M.B., and Harpole Jr. D.H. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin. Cancer Res. 9 (2003) 613-618
19. Leng L., Metz C.N., Fang Y., Xu J., Donnelly S., Baugh J., Delohery T., Chen Y., Mitchell R.A., and Bucala R. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197 (2003) 1467-1476
20. Liu H., Sadygov R.G., and Yates III J.R. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 76 (2004) 4193-4201
21. Lutterbach B., Zeng Q., Davis L.J., Hatch H., Hang G., Kohl N.E., Gibbs J.B., and Pan B.S. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 67 (2007) 2081-2088
22. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
23. Ma P.C., Jagadeeswaran R., Jagadeesh S., Tretiakova M.S., Nallasura V., Fox E.A., Hansen M., Schaefer E., Naoki K., Lader A., et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 65 (2005) 1479-1488
24. Mahadevan D., Cooke L., Riley C., Swart R., Simons B., Della Croce K., Wisner L., Iorio M., Shakalya K., Garewal H., et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 26 (2007) 3909-3919
25. Mahon F.X., Deininger M.W., Schultheis B., Chabrol J., Reiffers J., Goldman J.M., and Melo J.V. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96 (2000) 1070-1079
26. Mazzocca A., Coppari R., De Franco R., Cho J.Y., Libermann T.A., Pinzani M., and Toker A. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 65 (2005) 4728-4738
27. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., Lu K.V., Yoshimoto K., Huang J.H., Chute D.J., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353 (2005) 2012-2024
28. Minami Y., Shimamura T., Shah K., Laframboise T., Glatt K.A., Liniker E., Borgman C.L., Haringsma H.J., Feng W., Weir B.A., et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 26 (2007) 5023-5027
29. Mitelman F., Johansson B., and Mertens F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat. Genet. 36 (2004) 331-334
30. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., and Look A.T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263 (1994) 1281-1284
31. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10 (2006) 515-527
32. Old W.M., Meyer-Arendt K., Aveline-Wolf L., Pierce K.G., Mendoza A., Sevinsky J.R., Resing K.A., and Ahn N.G. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol. Cell. Proteomics 4 (2005) 1487-1502
33. Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., and Mann M. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127 (2006) 635-648
34. Ong S.E., Blagoev B., Kratchmarova I., Kristensen D.B., Steen H., Pandey A., and Mann M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1 (2002) 376-386
35. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
36. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101 (2004) 13306-13311
37. Peduto L., Reuter V.E., Shaffer D.R., Scher H.I., and Blobel C.P. Critical function for ADAM9 in mouse prostate cancer. Cancer Res. 65 (2005) 9312-9319
38. Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., Zha X.M., Polakiewicz R.D., and Comb M.J. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotechnol. 23 (2005) 94-101
39. Saeed A.I., Sharov V., White J., Li J., Liang W., Bhagabati N., Braisted J., Klapa M., Currier T., Thiagarajan M., et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34 (2003) 374-378
40. Samuels Y., and Velculescu V.E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3 (2004) 1221-1224
41. Samuels Y., Diaz Jr. L.A., Schmidt-Kittler O., Cummins J.M., Delong L., Cheong I., Rago C., Huso D.L., Lengauer C., Kinzler K.W., et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7 (2005) 561-573
42. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007) 561-566
43. Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J., Stevens C., O'Meara S., Smith R., Parker A., et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431 (2004) 525-526
44. Taguchi Y., Kondo T., Watanabe M., Miyaji M., Umehara H., Kozutsumi Y., and Okazaki T. Interleukin-2-induced survival of natural killer (NK) cells involving phosphatidylinositol-3 kinase-dependent reduction of ceramide through acid sphingomyelinase, sphingomyelin synthase, and glucosylceramide synthase. Blood 104 (2004) 3285-3293
45. Thomas R.K., Baker A.C., Debiasi R.M., Winckler W., Laframboise T., Lin W.M., Wang M., Feng W., Zander T., Macconnaill L.E., et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39 (2007) 347-351
46. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
47. Tracy S., Mukohara T., Hansen M., Meyerson M., Johnson B.E., and Janne P.A. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 64 (2004) 7241-7244
48. Ullrich A., and Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 61 (1990) 203-212
49. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
50. Walters D.K., Mercher T., Gu T.L., O'Hare T., Tyner J.W., Loriaux M., Goss V.L., Lee K.A., Eide C.A., Wong M.J., et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10 (2006) 65-75
51. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297 (2002) 63-64
52. Wolf-Yadlin A., Kumar N., Zhang Y., Hautaniemi S., Zaman M., Kim H.D., Grantcharova V., Lauffenburger D.A., and White F.M. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol. Syst. Biol. 2 (2006) 54
53. Zhang P., Gao W.Y., Turner S., and Ducatman B.S. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol. Cancer 2 (2003) 1
54. Zybailov B., Coleman M.K., Florens L., and Washburn M.P. Correlation of relative abundance ratios derived from peptide ion chromatograms and spectrum counting for quantitative proteomic analysis using stable isotope labeling. Anal. Chem. 77 (2005) 6218-6224